Duration of P2Y12 inhibitor Prescription After Percutaneous Coronary Intervention in Patients on Oral Anticoagulants (from NCDR CathPCI Registry)

被引：0
|
作者：
Saad, Marwan [1 ]
Tobolski, Jared [2 ]
Kolte, Dhaval [3 ]
Wang, Yongfei [4 ]
Minges, Karl [4 ]
Hira, Ravi S. [5 ]
Curtis, Jeptha P. [4 ]
Abbott, Jinnette Dawn [1 ]
机构：
[1] Brown Univ, Warren Alpert Med Sch, Cardiovasc Inst, Providence, RI 02912 USA
[2] Maine Med Ctr, Div Cardiol, Portland, ME USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02115 USA
[4] Yale Univ, Sch Med, Dept Internal Med, Sect Cardiovasc Med, New Haven, CT USA
[5] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2020年 / 133卷
关键词：
THERAPY;
D O I：
10.1016/j.amjcard.2020.07.029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：182 / 184
页数：5
相关论文
共 50 条
  • [1] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
    Zhou, Xuan
    Angiolillo, Dominick J.
    Ortega-Paz, Luis
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (10)
  • [2] Guided P2Y12 inhibitor therapy after percutaneous coronary intervention
    Sibbing, Dirk
    Kastrati, Adnan
    LANCET, 2021, 397 (10283): : 1423 - 1425
  • [3] The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
    Luo, Liman
    Fu, Menglu
    Li, Yuanyuan
    Chen, Zhihui
    Yu, Jing
    Luo, Jinlan
    Hu, Shuiqing
    Tu, Ling
    Xu, Xizhen
    CLINICAL CARDIOLOGY, 2020, 43 (03) : 235 - 241
  • [4] P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
    Capodanno, Davide
    Baber, Usman
    Bhatt, Deepak L.
    Collet, Jean-Philippe
    Dangas, George
    Franchi, Francesco
    Gibson, C. Michael
    Gwon, Hyeon-Cheol
    Kastrati, Adnan
    Kimura, Takeshi
    Lemos, Pedro A.
    Lopes, Renato D.
    Mehran, Roxana
    O'Donoghue, Michelle L.
    Rao, Sunil, V
    Rollini, Fabiana
    Serruys, Patrick W.
    Steg, Philippe G.
    Storey, Robert F.
    Valgimigli, Marco
    Vranckx, Pascal
    Watanabe, Hirotoshi
    Windecker, Stephan
    Angiolillo, Dominick J.
    NATURE REVIEWS CARDIOLOGY, 2022, 19 (12) : 829 - 844
  • [5] Sex Differences in the Prescription of P2Y12 Inhibitor Agents Following Percutaneous Coronary Intervention
    Laband, William
    Sedrakyan, Surik
    Khan, M. Faisal
    CIRCULATION, 2024, 150
  • [6] P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
    Davide Capodanno
    Usman Baber
    Deepak L. Bhatt
    Jean-Philippe Collet
    George Dangas
    Francesco Franchi
    C. Michael Gibson
    Hyeon-Cheol Gwon
    Adnan Kastrati
    Takeshi Kimura
    Pedro A. Lemos
    Renato D. Lopes
    Roxana Mehran
    Michelle L. O’Donoghue
    Sunil V. Rao
    Fabiana Rollini
    Patrick W. Serruys
    Philippe G. Steg
    Robert F. Storey
    Marco Valgimigli
    Pascal Vranckx
    Hirotoshi Watanabe
    Stephan Windecker
    Dominick J. Angiolillo
    Nature Reviews Cardiology, 2022, 19 : 829 - 844
  • [7] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?
    Feng, Wen-Han
    Hsieh, I-Chang
    Li, Yi-Heng
    ACTA CARDIOLOGICA SINICA, 2021, 37 (01) : 1 - 8
  • [8] Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
    Tantry, Udaya S.
    Navarese, Eliano P.
    Myat, Aung
    Gurbel, Paul A.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 60 (4-5) : 460 - 470
  • [9] P2Y12 blocker monotherapy after percutaneous coronary intervention
    F. W. A. Verheugt
    P. Damman
    S. A. J. Damen
    J. J. Wykrzykowska
    E. C. I. Woelders
    R. -J. M. van Geuns
    Netherlands Heart Journal, 2021, 29 : 566 - 576
  • [10] P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION
    Pil-Sang, Song
    Jin-Ok, Jeong
    JOURNAL OF HYPERTENSION, 2023, 41 : E178 - E178
12345